Teva Pharmaceutical Industries Limited (TEVA)
| Market Cap | 36.82B |
| Revenue (ttm) | 17.26B |
| Net Income (ttm) | 1.41B |
| Shares Out | 1.16B |
| EPS (ttm) | 1.21 |
| PE Ratio | 25.83 |
| Forward PE | 11.67 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 8,383,863 |
| Open | 31.19 |
| Previous Close | 31.26 |
| Day's Range | 31.09 - 31.84 |
| 52-Week Range | 14.81 - 37.35 |
| Beta | 0.76 |
| Analysts | Strong Buy |
| Price Target | 38.63 (+22.17%) |
| Earnings Date | Apr 29, 2026 |
About TEVA
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for TEVA stock is "Strong Buy." The 12-month stock price target is $38.63, which is an increase of 22.17% from the latest price.
News
Teva Pharmaceutical's Turnaround Is Working. Here's When to Buy the Stock.
Collectively, analysts tracking the stock expect declines in both revenue and profitability. The company continues to effect a major pivot in its business.
3 Catalysts That Could Send Teva Stock to $40 and Beyond
FDA approval of long-acting schizophrenia drug olanzapine could be Teva's biggest near-term catalyst. Teva's specialty drugs continue to gain momentum.
Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 3.6% -- What GF Score of 54 Tells Investors
Teva Pharmaceutical Industries Ltd (TEVA) Shares Surge 3.6% -- What GF Score of 54 Tells Investors
Notable ETF Inflow Detected - ACWX, SPOT, PDD, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ex US ETF (Symbol: ACWX) where we have detected an a...
Teva Launches Home Ground™ Schizophrenia Community, a New Online Resource Hub for People Living with Schizophrenia and Their Care Partners
PARSIPPANY, N.J. and TEL AVIV, Israel, April 15, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the launc...
Community Routes: Access to Mental Health Care Provides Continued Funding for Mental Health Services at Free & Charitable Clinics
Supplemental funding helps 11 free & charitable clinics and charitable pharmacies expand mental health care and reach more patients in underserved communities Supplemental funding helps 11 free & char...
TEVA's Price Target Raised by B of A Securities, Maintains 'Buy' Rating | TEVA Stock News
TEVA's Price Target Raised by B of A Securities, Maintains 'Buy' Rating | TEVA Stock News
Teva Pharmaceutical Industries Ltd (TEVA) Trading 3.32% Higher on Apr 8
Teva Pharmaceutical Industries Ltd (TEVA) Trading 3.32% Higher on Apr 8
Notable ETF Inflow Detected - ACWX, SPOT, TEVA, SUNB
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares MSCI ACWI ex US ETF (Symbol: ACWX) where we have detected an a...
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31
Teva Pharmaceutical Industries Ltd (TEVA) Stock Price Up 2.86% on Mar 31
Teva (TEVA) Advances with Biosimilar Application Review for Xolair
Teva (TEVA) Advances with Biosimilar Application Review for Xolair
FDA Approves Teva's (TEVA) Ponlimsi as Prolia Biosimilar
FDA Approves Teva's (TEVA) Ponlimsi as Prolia Biosimilar
Teva Pharmaceutical Industries Ltd (TEVA) Shares Down 3.49% on Mar 30
Teva Pharmaceutical Industries Ltd (TEVA) Shares Down 3.49% on Mar 30
Notable ETF Outflow Detected - FNDF, MDT, ZIM, TEVA
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Schwab Fundamental International Large Company Index (Symbol: FNDF) wh...
Teva Secures FDA Nod For PONLIMSI, Biosimilar Candidate To Xolair Applications Accepted By FDA & EMA
(RTTNews) - Teva Pharmaceutical Industries Limited (TEVA), Monday announced that the U.S. Food and Drug Administration has approved PONLIMSI as a biosimilar to Prolia, to treat a variety of debilitati...
Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)
TEL AVIV, Israel and PARSIPPANY, N.J., March 30, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced three milestones in its biosimilar portfolio, demons...
Insider Sell: Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Insider Sell: Mark Sabag Sells 62,102 Shares of Teva Pharmaceutical Industries Ltd (TEVA)
Teva Releases Q1 2026 Aide Memoire
TEL AVIV, Israel, March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2026 Aide Memoire is available on the “Investors” page on its...
Teva to Host Conference Call to Discuss First Quarter 2026 Financial Results at 8 a.m. ET on April 29, 2026
TEL AVIV, Israel and PARSIPPANY, N.J., March 19, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quar...
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Ltd at Barclays Global Healthcare Conference Transcript
Teva Pharmaceutical Industries Transcript: Barclays 28th Annual Global Healthcare Conference
The company accelerated its transformation to biopharma in 2025, with innovative products driving 35% growth and a robust late-stage pipeline targeting over $13 billion in peak sales. Key launches and data readouts are set for 2026 and beyond, while cost efficiency and disciplined capital allocation underpin strong EBITDA and free cash flow outlook.
Teva Pharmaceutical Industries Transcript: Leerink Global Healthcare Conference 2026
The company is accelerating its transformation into a biopharma leader, with strong growth in both generics and innovative products. Key assets like AUSTEDO, UZEDY, and a robust pipeline are expected to drive significant revenue and margin expansion, supported by strategic partnerships and disciplined capital allocation.
The 3 Best Stocks to Invest $1,000 in Right Now
Brookfield Corporation trades at a discount to its assets and holdings, and its value could continue to compound in the coming years. SSR Mining remains one of the best ways to capitalize on rising pr...
Zacks Industry Outlook Highlights Teva Pharmaceuticals, Sandoz and Dr. Reddy's
TEVA, Sandoz and Dr. Reddy's are shifting toward complex generics and biosimilars to counter pricing pressure and strengthen margins in the competitive generics market.
Forget Teva: This Dividend Top Dog Is the Real Value Buy Today
Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead.